ArticleAntibody therapeutics2026

Preclinical characterization of IBD0333, a novel CD24×4-1BB bispecific antibody with tumor-dependent agonistic activity for cancer immunotherapy.

Dong-Cheng Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.